Scientific Research
My research focuses on translating biological insights into meaningful advances for patients.
lncRNAs in B-Cell Malignancies
My research journey has spanned multiple areas of cancer biology and therapeutic development, from nanomedicine and cancer immunotherapy to RNA biology. During my undergraduate studies, I worked on doped TiO2 nanoparticles developed for photodynamic therapy. In my master's research, I focused on T-cell biology and cancer immunotherapy (CAR-T cell therapy). Today, as a PhD researcher at CEITEC, I study long non-coding RNAs (lncRNAs) and their role in B-cell malignancies.
My current research focuses on understanding how lncRNAs regulate B-cell biology and contribute to the pathophysiology of chronic lymphocytic leukemia (CLL). I identified an lncRNA involved in these processes, revealing a previously unexplored vulnerability in leukemia that could be further investigated as a potential therapeutic target and prognostic biomarker.
Across these projects, I have worked at the intersection of molecular biology, cancer research, and therapeutic development, gaining experience across distinct therapeutic modalities and disease mechanisms. My research has been published in Leukemia (Nature Portfolio), the Journal of Clinical Investigation, and Blood.
Peer-Reviewed Research
My research has been published in several of the field's most prestigious journals
For the complete list of my publications, visit My Google Scholar profile.
For Biotech Investors & Translational Research
I bring a research-driven approach to evaluating biological hypotheses, therapeutic mechanisms, and translational evidence — with a focus on what is genuinely supported by the data.
Target & Mechanism Assessment
I approach therapeutic targets as scientific hypotheses: What is the mechanism? How strong is the evidence? Is the finding reproducible? And does the biology hold up beyond the original experimental system? This framework is directly relevant to assessing emerging targets and early-stage biotech programs.
Translational & Clinical Interpretation
My work spans molecular biology and disease-relevant research, giving me a practical understanding of how mechanistic findings connect to clinical development. I am comfortable evaluating study design, endpoints, biomarkers, patient stratification, and the strength — and limitations — of translational claims.
Scientific Due Diligence
Training across MIT, Harvard, EMBL, and UCSF, together with publication in selective journals, has shaped a rigorous approach to evaluating evidence. I focus on separating compelling biology from preliminary signals, and promising mechanisms from genuinely actionable opportunities.
Interested in my research background?
I'm open to research, consulting, and scientific advisory roles, including opportunities in Biotech VC.
Get in Touch →